Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

BCX9930 para o tratamento de C3G, IgAN e PMN (RENEW) (RENEW)

27 de outubro de 2026 atualizado por: BioCryst Pharmaceuticals

Um estudo aberto, de segurança, tolerabilidade e prova de conceito da terapia oral BCX9930 em indivíduos com C3G, IgAN ou PMN

The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

2

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Barcelona, Espanha
        • Investigative Site #1
      • Barcelona, Espanha
        • Investigative Site #2
      • Madrid, Espanha
        • Investigative Site #1
      • Madrid, Espanha
        • Investigative Site #2
      • Poitiers, França
        • Investigative Site
      • Toulouse, França
        • Investigative Site
      • Bari, Itália
        • Investigative Site
      • Bergamo, Itália
        • Investigative Site
      • Brescia, Itália
        • Investigative Site
      • Turin, Itália
        • Investigative Site
      • Oxford, Reino Unido
        • Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Body weight ≥ 40 kilograms (kg)
  • Primary diagnosis of C3G, IgAN, or PMN confirmed by central pathology review
  • An estimated glomerular filtration rate (eGFR) ≥ 50 milliter per minute per 1.73 meter square (mL/min/1.73 m^2) (or ≥ 30 mL/min/1.73 m^2 after Data Monitoring Committee [DMC] recommendation)
  • Receiving treatment with a stable, maximum recommended or maximum tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 60 days prior to the Day 1 Visit
  • Documentation of current vaccinations against Neisseria meningitidis and Streptococcus pneumoniae or willingness to start vaccination series

Exclusion Criteria:

  • Known congenital deficiency of C1s, C1r, C1q, C2, or C4
  • History of hematopoietic cell transplant or solid organ transplant or anticipated candidate for transplantation
  • Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or current and uncontrolled clinically significant cardiovascular or cerebrovascular condition
  • History of malignancy within 5 years prior to the screening visit
  • Active serious bacterial, viral, or fungal infection or any other serious infection within 14 days of screening
  • Treatment with any systemic immunosuppressive or immunomodulatory therapy within 90 days OR anti-CD20 antibody therapies (eg, rituximab) within 180 days prior to the screening visit
  • Treatment with renin inhibitors (eg, aliskiren) or sodium-glucose-cotransporter 2 (SGLT2) inhibitors within 60 days prior to Day 1

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: C3G cohort

Approximately 14 eligible participants with C3G will be enrolled.

Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Experimental: IgAN cohort

Approximately 14 eligible participants with IgAN will be enrolled.

Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Experimental: PMN cohort

Approximately 14 eligible participants with PMN will be enrolled.

Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percent Change From Baseline in 24-hour uPCR at Week 12
Prazo: Baseline, Week 12

Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease.

Baseline, Week 12
Percent Change From Baseline in 24-hour uPCR at Week 24
Prazo: Baseline, Week 24

Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease.

Baseline, Week 24

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Alteração percentual da linha de base na excreção urinária de proteínas em 24 horas
Prazo: Linha de base, semanas 12, 24,
Linha de base, semanas 12, 24,
Change From Baseline in Estimated Glomerular Filtration Rate
Prazo: Baseline, Weeks 12, 24

eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula for participants ≥ 18 years old and by the bedside Schwartz formula for participants ≤ 18 years old. eGFR was reported in milliliter per minute per 1.73 per square meter (mL/min/1.73m^2).

Baseline, Weeks 12, 24
Number of Participants With a Treatment-emergent Adverse Event (TEAE)
Prazo: From first dose up to safety follow-up period (Week 28)

An Adverse event (AE) was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

From first dose up to safety follow-up period (Week 28)
Number of Participants Who Discontinued Due to a TEAE
Prazo: From first dose up to safety follow-up period (Week 28)

An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

From first dose up to safety follow-up period (Week 28)
Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE)
Prazo: From first dose up to safety follow-up period (Week 28)

An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

A serious adverse event (SAE) was an adverse event/reaction that results in any of the following outcomes:

  • Death
  • Is life-threatening (participant was at immediate risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe)
  • Requires participant hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization
  • Results in persistent or significant disability/incapacity (ie, there was a substantial disruption of a person's ability to carry out normal life functions)
  • Is a congenital anomaly/birth defect
From first dose up to safety follow-up period (Week 28)
Number of Participants Who Experienced a Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 TEAE
Prazo: From first dose up to safety follow-up period (Week 28)

An AE was any untoward medical occurrence has no causal relationship with the study drug or with the clinical study itself. It was an unfavorable & unintended sign, symptom, syndrome, or illness that developed or worsened during clinical study.

TEAEs: AEs that started on or after first dose of treatment through 30 days after the last dose of study drug. All AEs were graded using the CTCAE Grades 1 through 5.

Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated

Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL)

Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL

Grade 4: Life-threatening consequences; urgent intervention indicated

Grade 5: Death

Participants with Grades 3 or 4 AEs were reported

From first dose up to safety follow-up period (Week 28)
Number of Participants Who Experienced a CTCAE Treatment-emergent Grade 3 or 4 Laboratory Abnormality
Prazo: From first dose up to safety follow-up period (Week 28)

Treatment-emergent Laboratory Abnormality were defined as an event that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

CTCAE Grades for laboratory abnormalities include:

Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.

Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.

Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.

Grade 4: Life-threatening consequences; urgent intervention indicated.

Grade 5: Death

Participants with Grades 3 or 4 laboratory abnormality were reported.

From first dose up to safety follow-up period (Week 28)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Carla M Nester, MD, MSA, FASN, University of Iowa Stead Family Children's Hospital

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

18 de fevereiro de 2022

Conclusão Primária (Real)

23 de setembro de 2022

Conclusão do estudo (Real)

23 de setembro de 2022

Datas de inscrição no estudo

Enviado pela primeira vez

26 de novembro de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de dezembro de 2021

Primeira postagem (Real)

17 de dezembro de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever